Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Double Blind, Randomized, Placebo-controlled Trial Evaluating the Efficacy and Safety of Nintedanib Over 52 Weeks in Patients With Progressive Fibrosing Interstitial Lung Disease (PF-ILD)

Next Previous
Trial Profile

A Double Blind, Randomized, Placebo-controlled Trial Evaluating the Efficacy and Safety of Nintedanib Over 52 Weeks in Patients With Progressive Fibrosing Interstitial Lung Disease (PF-ILD)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 27 Dec 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nintedanib (Primary)
  • Indications Interstitial lung diseases
  • Focus Registrational; Therapeutic Use
  • Acronyms INBUILD
  • Sponsors Boehringer Ingelheim; Boehringer Ingelheim Pharma KG

Most Recent Events

  • 22 Dec 2023 Results investigating the effects of nintedanib on the symptoms and impact of pulmonary fibrosis in patients with progressive pulmonary fibrosis (PPF) using the Living with Pulmonary Fibrosis (L-PF) questionnaire, published in the European Respiratory Journal
  • 26 Sep 2023 Results assessing efficacy of nintedanib on slowing decline in FVC across subgroups in the trial by the baseline characteristics over 52 weeks compared with placebo published in the Advances in Therapy.
  • 13 Sep 2023 Results presented at the 33rd Annual Congress of the European Respiratory Society

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top